MGI Tech said its DNBSeq-T1+ sequencer received medical device registration from China’s NMPA, enabling deployment in the Chinese clinical market. The benchtop instrument targets applications including cancer diagnostics, rare disease testing, and genetic screening. The platform can generate up to 1.2 terabases of data per day across two flow cells, completing a paired-end 150 bp run in about 24 hours. MGI said the balance of speed, throughput, and footprint is designed to be “clinical application friendly.” The regulatory clearance strengthens competition in China’s sequencing-instrument market as more platform vendors seek clinical workflows beyond research use, while also supporting the scaling of genomics-based testing capacity in routine care.